Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 17Lymphoid 13Other solid neoplasm 6Dermatologic 6Sarcoma 3Plasma cell 2Myeloid 2Genitourinary 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Multiple Myeloma 2Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 139Lenalidomide 75Cyclophosphamide 73Bortezomib 73Calcium Dobesilate 57fludarabine 49pomalidomide 43daratumumab 39fludarabine phosphate 34carfilzomib 33Melphalan 29dexamethasone acetate 24dexamethasone 21-phosphate 24auricularum 22Filgrastim 18Whole-Body Irradiation 15Biopsy 14ixazomib 13isatuximab 13Magnetic Resonance Spectroscopy 13Granulocyte Colony-Stimulating Factor 13Vorinostat 12Tacrolimus 12Specimen Handling 12Sirolimus 12Peripheral Blood Stem Cell Transplantation 12venetoclax 11belantamab mafodotin 11Rituximab 11Panobinostat 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × tanespimycin × Plasma cell × Clear all
NCT00303797 2013-03-19

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
50 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00113204 2008-05-20

IPi-504-01

Infinity Pharmaceuticals, Inc.

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Hematologic Diseases, Multiple Myeloma, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡